What is the official ID of this bill?
The official print number for this legislation is S 2129.
Mandating Lower-Cost Generics and Biosimilars Inclusion in Medicare Part D.
This Act requires Medicare Part D prescription drug plans to include lower-cost generic drugs and biosimilar products on their formularies if they cover the corresponding higher-cost brand-name drugs. The goal is to reduce out-of-pocket costs for seniors by mandating significantly lower copayments (at least $20 less) for these cheaper alternatives. Furthermore, plans are prohibited from imposing stricter access limits on generics than on brand-name drugs.
Key points
Starting January 1, 2025, Medicare Part D plans must include cheaper generic and biosimilar versions if the brand-name reference drug is covered.
Plans must create a dedicated cost-sharing tier for generics and biosimilars with copayments at least $20 lower than the lowest brand-drug tier.
Access restrictions (like prior authorization or step therapy) cannot be more restrictive for the lower-cost generic/biosimilar than for the original brand drug.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.